Baxter raises its quarterly dividend

Baxter, supplier of pharmaceutical products, has revealed a rise in its quarterly dividend.

The company’s board of directors declared a quarterly dividend of $0.29 (17p) per Baxter common share, marking an increase over the previous quarterly rate of $0.26 per share.

This represents a rise of 12 per cent, the firm revealed.

On January 5th 2010, the dividend will be payable to shareholders of record as of the close of business on December 10th 2009.

Baxter, which develops, manufactures and markets products dealing with conditions such as immune disorders, infectious diseases and trauma, is a global firm that also operates through various subsidiaries.

In September, it announced that it remains in a promising position to maximise its future prospects.

Speaking at the time, Robert Parkinson, the company’s chairman and chief executive officer, stated: “We believe we have a balanced outlook and are well-positioned to achieve our results.”